{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:42:54Z","timestamp":1648600974487},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SEMERGEN - Medicina de Familia"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.semerg.2012.01.006","type":"journal-article","created":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T16:00:58Z","timestamp":1336665658000},"page":"366-376","source":"Crossref","is-referenced-by-count":1,"title":["Prevenci\u00f3n primaria con aspirina"],"prefix":"10.1016","volume":"38","author":[{"given":"J.A.","family":"Divis\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Galgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Polo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Dur\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2012.01.006_bib0005","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1001\/jama.1912.04270120001001","article-title":"Clinical features of sudden obstruction of the coronary arteries","volume":"59","author":"Herrick","year":"1912","journal-title":"JAMA"},{"key":"10.1016\/j.semerg.2012.01.006_bib0010","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0300-8932(00)75163-3","article-title":"Control de la colesterolemia en Espa\u00f1a, 2000. Un instrumento para la prevenci\u00f3n cardiovascular","volume":"53","author":"Plaza P\u00e9rez","year":"2000","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.semerg.2012.01.006_bib0015","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1157\/13119995","article-title":"Enfermedad aterotromb\u00f3tica coronaria: avances en el tratamiento antiplaquetario","volume":"61","author":"Badimon","year":"2008","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.semerg.2012.01.006_bib0020","first-page":"2823","article-title":"Antiagregantes Plaquetarios","volume":"8","author":"P\u00e1ramo Fern\u00e1ndez","year":"2001","journal-title":"Medicine"},{"key":"10.1016\/j.semerg.2012.01.006_bib0025","first-page":"2","article-title":"Mecanismo de acci\u00f3n de los f\u00e1rmacos antitromb\u00f3ticos","volume":"6","author":"Arzamendi","year":"2006","journal-title":"Rev Esp Cardiol Supl"},{"key":"10.1016\/j.semerg.2012.01.006_bib0030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","article-title":"Randomised trial of prophylactic daily aspirin in British male doctors","volume":"296","author":"Peto","year":"1988","journal-title":"BMJ"},{"key":"10.1016\/j.semerg.2012.01.006_bib0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing physician\u015bhealth study","volume":"321","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2012.01.006_bib0040","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2012.01.006_bib0045","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2012.01.006_bib0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2012.01.006_bib0055","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomised trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2012.01.006_bib0060","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1001\/jama.1992.03490100090033","article-title":"Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14","volume":"268","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.semerg.2012.01.006_bib0065","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.semerg.2012.01.006_bib0070","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.semerg.2012.01.006_bib0075","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/archneur.57.3.326","article-title":"Aspirin for the primary prevention of stroke and other mayor vascular events","volume":"57","author":"Hart","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1016\/j.semerg.2012.01.006_bib0080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevenci\u00f3n of death, myocardial infarction and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.semerg.2012.01.006_bib0085","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.295.3.306","article-title":"Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials","volume":"295","author":"Berger","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.semerg.2012.01.006_bib0090","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials","volume":"373","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2012.01.006_bib0095","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b4531","article-title":"Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomized controlled trials","volume":"339","author":"De Berardis","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.semerg.2012.01.006_bib0100","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.diabres.2009.09.029","article-title":"Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis","volume":"87","author":"Zhang","year":"2010","journal-title":"Diab Res Clin Pract"},{"key":"10.1016\/j.semerg.2012.01.006_bib0105","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.2337\/dc09-1297","article-title":"Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Review and Meta- Analysis Comparing Patients With and Without Diabetes","volume":"32","author":"Calvin","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semerg.2012.01.006_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.hjr.0000277983.23934.c9","article-title":"European guideline on cardiovascular disease prevention in clinical practice: full text","volume":"14","author":"Graham","year":"2007","journal-title":"Eur J Card Prev Rehab"},{"key":"10.1016\/j.semerg.2012.01.006_bib0115","unstructured":"World Health Organization Prevention of cardiovascular disease: Guidelines for assessment and management of cardiovascular risk. Disponible en: <http:\/\/www.who.int\/cardiovascular_diseases\/guidelines\/Full%20text.pdf"},{"key":"10.1016\/j.semerg.2012.01.006_bib0120","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/CIRCULATIONAHA.107.181546","article-title":"Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update","volume":"115","author":"Mosca","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.semerg.2012.01.006_bib0125","doi-asserted-by":"crossref","first-page":"396","DOI":"10.7326\/0003-4819-150-6-200903170-00008","article-title":"Aspirin for the prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation Statement","volume":"150","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semerg.2012.01.006_bib0130","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","article-title":"Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document","volume":"27","author":"Mancia","year":"2009","journal-title":"J Hypertens"},{"key":"10.1016\/j.semerg.2012.01.006_bib0135","unstructured":"National Collaborating Centre for Chronic Conditions Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). London: Royal College of Physicians, reprint 2009."},{"key":"10.1016\/j.semerg.2012.01.006_bib0140","unstructured":"Grupo de trabajo de la Gu\u00eda de Pr\u00e1ctica Cl\u00ednica sobre Diabetes tipo 2. Gu\u00eda de Pr\u00e1ctica Cl\u00ednica sobre Diabetes tipo 2. Madrid: Plan Nacional para el SNS del MSC. Agencia de Evaluaci\u00f3n de Tecnolog\u00edas Sanitarias del Pa\u00eds Vasco; 2008. Gu\u00edas de Pr\u00e1ctica Cl\u00ednica en el SNS: OSTEBA N\u00b0 2006\/08."},{"key":"10.1016\/j.semerg.2012.01.006_bib0145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2337\/dc10-S011","article-title":"Standards of Medical Care in Diabetes\u20132010","volume":"33","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semerg.2012.01.006_bib0150","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2337\/dc10-0555","volume":"33","author":"Pignone","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semerg.2012.01.006_bib0155","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","article-title":"Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes","volume":"108","author":"Peters","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.semerg.2012.01.006_bib0160","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/j.1572-0241.2000.02248.x","article-title":"Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin","volume":"95","author":"Sorensen","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semerg.2012.01.006_bib0165","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJMoa042087","article-title":"Clopidogrel vs aspirin and esomeprazol to prevent recurrent ulcer bleeding","volume":"352","author":"Chan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2012.01.006_bib0170","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1157\/13091885","article-title":"Evaluaci\u00f3n econ\u00f3mica del tratamiento con \u00e1cido acetilsalic\u00edlico en dosis bajas en la prevenci\u00f3n primaria de enfermedades cardiovasculares","volume":"59","author":"Lamotte","year":"2006","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.semerg.2012.01.006_bib0175","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1161\/CIRCULATIONAHA.107.735340","article-title":"Cost-Effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk","volume":"117","author":"Greving","year":"2008","journal-title":"Circulation"}],"container-title":["SEMERGEN - Medicina de Familia"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359312000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359312000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T14:50:53Z","timestamp":1542984653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359312000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S1138359312000263"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2012.01.006","relation":{},"ISSN":["1138-3593"],"issn-type":[{"value":"1138-3593","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}